Heat-stable ritonavir approved, ending treatment stranglehold for people living with HIV/AIDSread more
Make It Happen Campaign Update: UNITAID Board still discussing finer details of the Patent Pool Entity read more
New European Parliament Working Group on Innovation & Access launches with support of Access Campaign read more
U.S. health care legislation could limit access read more
MSF responds to World Health Organization’s new HIV treatment guidelines read more
MSF sends letter to EU Ministers of Health regarding antibiotic resistance read more
 |
 |
|
 |
Company: Boehringer Ingelheim
Headquarters: Ingelheim, Germany
These are the drug patents we want Boehringer Ingelheim to put in the pool and why patients need them:
Nevirapine (NVP)
Brand name: Viramune
This drug is used by people starting out on antiretroviral therapy. Like other HIV drugs, it is taken in combination with other drugs. Putting this drug in the pool will open the way to simplified treatment for patients by creating more easy to take, three-in-one combination tablets.
Tipranavir (TPV)
Brand name: Aptivus
Tipranavir is a drug that can be used to treat children who have grown resistant to their original antiretroviral treatment. There are a very limited number of drugs of this class (known as protease inhibitors or PIs) produced in child dosages that are available in developing countries and putting the patents for this drug in the pool could help to increase the treatment options for treating children with HIV over two years of age
People Living with HIV/AIDS: India must not sacrifice us in trade agreement with Europe
Indian Court Gives Boost to Access to Medicines As Latest Appeal By Bayer is Rejected
UNITAID Patent Pool: Innovative Initiative Designed to Boost Access to Medicines is Adopted
MSF Clinical Officer Olesi Ellemani Pasulani's reflections on AIDS treatment in Malawi
Living with MDR TB: 'Expert Client' Nonkululeko Mamba's Story
MDR TB Treatment in Cambodia: A Catalyst for Change
